Sillajen’s co-development agreement of renal cancer treatment with U.S. RegeneronPharmaceuticals

Published: 2017-05-10 16:27:00
Updated: 2017-05-10 15:37:21

Sillajen(CEO Eun-Sang Moon) announced in a joint statement on the 8th that it signed a co-research agreement of renal cell carcinoma(renal cancer) treatment development with U.S. ‘RegeneronPharmaceuticals.’

Under the agreement, the two companies are planning to conduct a Phase 1b clinical trial ...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email:

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.